-
New data from a Phase 3 clinical trial, TAPPAS, evaluating TRACON Pharmaceuticals' (NASDAQ:TCON) TRC105, combined with Novartis' (NVS -0.4%) Votrient (pazopanib), in angiosarcoma patients showed a treatment effect in some patients. The results were presented at the CTOS annual meeting in Rome.
- 35% (n=18/51) of patients experienced more than a 2x reduction in endoglin + circulating tumor cells (CTCs) while 25% (n=13/51) experienced more than a 10x reduction.
- An almost equal proportion (37%; n=19/51), however, experienced more than a 2x increase in endoglin + CTCs, including 25% (n=13/51) with more than a 10x increase.
- 27% (n=14/51) of patients experienced no significant change in endoglin + CTCs.
-
TRC105 (carotuximab) is an antibody that binds to a protein called endoglin which is overexpressed on proliferating endothelial cells that play an essential role in angiogenesis (formation of new blood vessels).
- TCON is up 7% in early trade.